Arcadia Biosciences (RKDA) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - Arcadia Biosciences reported a quarterly loss of $0.87 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.77, and an improvement from a loss of $1.83 per share a year ago, indicating a significant year-over-year improvement [1] - The company posted revenues of $1.54 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 9.94%, although this represents a slight decline from year-ago revenues of $1.6 million [2] - Over the last four quarters, Arcadia Biosciences has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Arcadia Biosciences shares have increased approximately 35.5% since the beginning of the year, outperforming the S&P 500's gain of 25.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $1.45 million, and for the current fiscal year, it is -$1.70 on revenues of $5.41 million [7] Industry Outlook - The Agriculture - Products industry, to which Arcadia Biosciences belongs, is currently ranked in the bottom 16% of over 250 Zacks industries, suggesting a challenging environment [8] - The performance of Arcadia Biosciences stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]